Abstract Background Atezolizumab plus bevacizumab is the standard-of-care systemic regimen for advanced hepatocellular carcinoma (HCC). Accessible prognostic indicators are valuable in real-world p...
<p><strong>Tác giả:</strong> Tuan Anh Pham, Thi Thu Huong Nguyen, Thang Vu Hong, Quốc Hoàn Chử, Thi Yen Le, Xuan Dai Nguyen, Quang Huy Do, Van Quang Le, Duy Manh Pham</p>
<p>Abstract Background Atezolizumab plus bevacizumab is the standard-of-care systemic regimen for advanced hepatocellular carcinoma (HCC). Accessible prognostic indicators are valuable in real-world practice, particularly in populations with a high burden of hepatitis B virus (HBV). Objective To evaluate the prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) and determine a pragmatic, clinically interpretable threshold for risk stratification. Materials and methods This retros...</p>
<p>📄 DOI: <a href="https://doi.org/https://doi.org/10.1186/s12876-026-05507-9" target="_blank" rel="noopener">https://doi.org/10.1186/s12876-026-05507-9</a></p>
<p>📖 <a href="https://doi.org/https://doi.org/10.1186/s12876-026-05507-9" target="_blank" rel="noopener">Xem bài báo đầy đủ</a></p>
Bài viết được biên soạn lại bởi LIFVietnam. Nguồn tham khảo: OpenAlex
